European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.
Institute of Cancer Research